Cirrhotic cardiomyopathy

Abstract

Increased cardiac output was first described in patients with cirrhosis more than fifty years ago. Later, various observations have indicated the presence of a latent cardiac dysfunction, which includes a combination of reduced cardiac contractility with systolic and diastolic dysfunction and electrophysiological abnormalities. This syndrome is termed cirrhotic cardiomyopathy. Results of experimental studies indicate the involvement of several mechanisms in the pathophysiology, such as reduced beta-adrenergic receptor signal transduction, altered transmembrane currents and electromechanical coupling, nitric oxide overproduction, and cannabinoid receptor activation. Systolic incompetence in patients can be revealed by pharmacological or physical strain and during stressful procedures, such as transjugular intrahepatic portosystemic shunt insertion and liver transplantation. Systolic dysfunction has recently been implicated in development of renal failure in advanced disease. Diastolic dysfunction reflects delayed left ventricular filling and is partly attributed to ventricular hypertrophy, subendocardial oedema, and altered collagen structure. The QT interval is prolonged in about half of the cirrhotic patients and it may be normalised by beta-blockers. No specific therapy for cirrhotic cardiomyopathy can be recommended, but treatment should be supportive and directed against the cardiac dysfunction. Future research should better describe the prevalence, impact on morbidity and survival, and look for potential treatments.

Albumin in chronic liver disease: structure, functions and therapeutic implications

“…Albumin has multifunctional properties which are impaired in the setting of cirrhosis and ACLF due to reduced concentration and structure changes including irreversible oxidation and altered isoforms. This may contribute to a wide range of biologic effects and clinical complications as well as correlate with overall survival Table 1 Currently established and potential future therapeutic indications for albumin in cirrhosis with their associated clinical benefits Hepatol Int Treatment of type-1 hepatorenal syndrome Hepatorenal syndrome (HRS) is a severe and progressive functional renal failure occurring in patients with cirrhosis and ascites characterized by splanchnic arterial vasodilatation in association with cardiac dysfunction [50]. The resultant circulatory dysfunction with renin-angiotensin and sympathetic system activation causes renal hypoperfusion and organ dysfunction.…”

The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?

“…It is characterized by the presence of systolic or diastolic dysfunction, and electrophysiological abnormalities that differ from alcoholic heart disease. Underlying pathophysiology includes reduced badrenergic receptor signal transduction, altered transmembrane currents and electromechanical coupling, nitric oxide overproduction, and cannabinoid receptor activation [106].…”

Non invasive continuous hemodynamic evaluation of cirrhotic patients after postural challenge

“…Recent studies documented the clinical impact of cardiovascular abnormalities in cirrhotic patients [17] , especially when submitted to surgical procedures, such as TIPS insertion [6,7,18] and liver transplantation [19] . Sampathkumar and colleagues [19] reported severe myocardial dysfunction in 1% of patients after liver transplantation, since during reperfusion, the return of a significant volume to the heart can unmask any diastolic dysfunction.…”